Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04720001 · ClinicalTrials.gov registry record
Florbetaben PET Imaging in PPA
A clinical trial of Alzheimer Disease and Primary Progressive Aphasia, sponsored by University of Chicago.
- Completed
- Registry status
- 1
- Enrollment target
- 1
- Study location
NCT04720001 is a study of Alzheimer Disease and Primary Progressive Aphasia that has completed, run by University of Chicago. The registered enrollment target is 1 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04720001, a study of Alzheimer Disease and Primary Progressive Aphasia, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to better understand how dementia affects activity in different parts of the brain.
Conditions Studied
Interventions
- DEVICE PET
- DRUG Florbetaben F18
Study Locations (1)
Illinois
- University of Chicago - American School Building - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-08-23 |
| Est. Completion | 2021-02-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04720001
The ClinicalTrials.gov registry entry for NCT04720001 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which PET is the first listed.
NCT04720001 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04720001 about?
NCT04720001 is a clinical study titled "Florbetaben PET Imaging in PPA". The purpose of this research is to better understand how dementia affects activity in different parts of the brain.
What is the current status of trial NCT04720001?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2018-08-23. Estimated completion is 2021-02-26.
What conditions does trial NCT04720001 study?
This clinical trial studies the following conditions: Alzheimer Disease, Primary Progressive Aphasia.
What interventions are being tested in trial NCT04720001?
The interventions under investigation include: PET (DEVICE), Florbetaben F18 (DRUG).
Who is sponsoring clinical trial NCT04720001?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04720001 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.